Press release
Savara to Participate in Three Upcoming Investor Conferences
Jefferies London Healthcare Conference Piper Sandler 34th Annual Healthcare Conference Evercore ISI 5th Annual HealthCONx Conference AUSTIN, Texas--(BUSINESS
About this update from Savara, Inc.
[{"type":"text","content":"\nJefferies London Healthcare Conference\n\nPiper Sandler 34th Annual Healthcare Conference\n\nEvercore ISI 5th Annual HealthCONx Conference\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nSavara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate at the following investor healthcare conferences:\n\nJefferies London Healthcare Conference\nNovember 16, 2022 at 9:35am PT/ 12:35pm ET / 5:35pm GMT\nCorporate Presentation\nWaldorf Hilton, London, UK\n\nPiper Sandler 34th Annual Healthcare Conference\nNovember 29, 2022 at 5:00am PT / 8:00am ET\nCorporate Presentation\nLotte New York Palace, New York City, NY\n\nEvercore ISI 5th Annual HealthCONx Conference\nNovember 30, 2022 at 10:50am PT / 1:50pm ET\nFireside Chat\nVirtual Conference\n\nA webcast of each presentation will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.\n\nAbout Savara\n\nSavara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20221109005637/en/\n\nSavara Inc. IR & PR\nAnne Erickson ([email protected])\n(512) 851-1366\n\nSource: Savara Inc.","length":5193,"tagName":"div"}]